Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia
Status:
Unknown status
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/II multi-center, open label, dose escalation study to identify the maximum
tolerated dose (MTD) of liposomal annamycin and to evaluate the safety of liposomal annamycin
in patients with refractory or relapsed acute lymphocytic leukemia.